Nonapeptide-1

Skin color depends largely on melanocytes, the pigment-making cells of the epidermis. When α-MSH binds the melanocortin-1 receptor (MC1R) on these cells, cyclic AMP rises and raises MITF, a transcription factor that drives tyrosinase and other melanin-building enzymes¹. Nonapeptide-1 is designed to compete with α-MSH at MC1R without passing the signal on.

In a cell study that used it as a comparison for tea polyphenols, it lowered melanin content, tyrosinase activity, and levels of MITF and the pigment enzymes TRP-1 and TRP-2 in cultured human melanocytes, with or without UVA exposure, and it also reduced MC1R levels¹. Whether enough intact peptide crosses living skin to reach melanocytes has not been shown in the studies we found.

Nearly all of the evidence is from cell culture. In human melanocytes and keratinocytes exposed to UVA, nonapeptide-1 reduced melanin and pigment-enzyme levels without changing how much α-MSH the cells made, which the authors read as an effect at the receptor¹.

A 2024 study attached nonapeptide-1 to silica nanoparticles loaded with the green-tea compound EGCG and reported less melanin and less UV-related DNA damage in laboratory and in vivo experiments; the work centered on EGCG delivery, so it says little about the peptide alone².

In people, the only controlled data found involve a combination product: in a 46-person melasma pilot trial, a formulation containing nonapeptide-1, phenylethyl resorcinol, other actives, and sunscreen was compared with sunscreen alone after initial triple-combination therapy. Melanin and severity scores improved in the formulation group, but the difference from sunscreen alone was not statistically significant³. No study has measured nonapeptide-1 by itself in human skin.

Not approved as a drug by the FDA or any other regulator found; it is used as a cosmetic ingredient. In the US, cosmetic ingredients do not need FDA approval before they go on the market, but a product claimed to decrease melanin production is regulated as a drug⁴.

No published study reports side effects of nonapeptide-1 on its own, and there are no long-term human data. The melasma pilot that used it in a combination product set out to assess tolerability, but its abstract does not describe adverse reactions³. As with any topical cosmetic, the finished product can irritate skin or cause contact allergy.

1. Chen et al., Postepy Dermatol Alergol 2022PubMed
2. Huang et al., Int J Pharm 2024PubMed
3. Chatterjee et al., Indian J Dermatol Venereol Leprol 2021PubMed
4. FDA: Is it a cosmetic, a drug, or both?FDA